CAS NO: | 11006-33-0 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
Cas No. | 11006-33-0 |
别名 | 腐草霉素,Zeocin |
化学名 | (2R,3S,4S,5R,6R)-2-(((2R,3S,4S,5S,6S)-2-(2-(6-amino-2-(3-amino-1-((2,3-diamino-3-oxopropyl)amino)-3-oxopropyl)-5-methylpyrimidine-4-carboxamido)-3-((5-((1-((2-(4-((4-guanidinobutyl)carbamoyl)-4',5'-dihydro-[2,4'-bithiazol]-2'-yl)ethyl)amino)-3-hydroxy-1-o |
Canonical SMILES | NC(CNC(CC(N)=O)C1=NC(N)=C(C(C(NC(C(NC(C(C(C)C(NC(C(NCCC2=NC(C3=NC(C(NCCCCNC(N)=N)=O)=CS3)CS2)=O)C(O)C)=O)O)C)=O)C(O[C@H]4[C@]([H])([C@H]([C@@H]([C@@H](O4)CO)O)O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@@H]5O)OC(N)=O)O)CO)C6=CNC=N6)=O)=N1)C)C(N)=O.[Cu+2].Cl |
分子式 | C55H85N20O21S2Cu o HCl |
分子量 | 1526.5 |
溶解度 | ≤10mg/ml in PBS, pH 7.2 |
储存条件 | Store at 2-8°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Phleomycin is a glycopeptide antibiotic. Glycopeptide antibiotics, a class of agents of microbial origin, are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Significant glycopeptide antibiotics include the anti-infective and antitumor antibiotics. In vitro: Previous study found that the chromosomes could be cleaved into nucleosomes and degraded by phleomycin over significantly narrower dose ranges than by bleomycin. In addition, phleomycin also showed lower specificity for internucleosomal cleavage than bleomycin. Moreover, it was found that the higher reactivity of phleomycin did not solely result from its higher rate of internucleosomal and intranucleosomal chromatin cleavage, since short phleomycin reactions always led to more extensive chromatin cleavage at low concentrations [1]. In vivo: A study of the in-vivo effects of phleomycin on meiosis of the mouse egg demonstrated a spectrum of damage to both first metaphase and second metaphase with polar body. The minimal effective dose in vivo of 2.5 μg/g of body weight could alter 28.3% of first metaphase figures and 50% of second metaphase cells [2]. Clinical trial: So far, no clinical study has been conducted. References: |